ANVS News

Annovis to Host Corporate Update Webinar on January 28, 2026

Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group

Annovis Announces Two Presentations at the CTAD 2025 Conference

Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study

Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients

Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program

Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules

Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock

Annovis Announces $6 Million Registered Direct Offering of Common Stock